NCT05249569 - Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Axitinib

Axitinib to be administered orally BID

DRUG

Avelumab

Avelumab to be administered as a 1-hour IV infusion on Day 1 and Day 15 of each 28-day cycle.

DRUG

Bavituximab

Bavituximab to be administered weekly on Days 1, 8, 15 and 22 of the 28-day cycle.

Trial Locations (1)

The University of Texas Southwestern Medical Center, Dallas